CLAIMS

USE OF PACAP FOR THE TREATMENT OF VIRAL INFECTIONS IN AQUATIC ORGANISMS

1. "Pituitary Adenylate Cyclase Activating Polypeptide" (PACAP) for ~~Use~~ use ~~of~~ in the ~~"Pituitary Adenylate Cyclase Activating Polypeptide" (PACAP) in the manufacture of a composition for the~~ treatment of viral infections and infectious diseases caused by viruses in aquatic organisms.

2. ~~The use of claim 1~~ PACAP for use according to claim 1, wherein the PACAP is ~~obtained a) by isolation from its~~ natural ~~source~~, ~~b)~~ synthetically or ~~c) by~~ recombinant ~~DNA technology~~.

3. ~~The use of~~ PACAP for use according to claim 2, wherein the PACAP is a ~~polypeptide sequence isolated from~~ natural fish PACAP.

4. ~~The use of~~ PACAP for use according to claims 1 to 3, wherein the PACAP is used in an aquatic organism selected from the group consisting of salmonids, penaeid shrimps and bivalves.

5. ~~The use of~~ PACAP for use according to claim 1, wherein the PACAP is used in the therapeutic treatment of viral infections caused by viruses of the *Herpesviridae, Papovaviridae, Togaviridae, Retroviridae, Reoviridae, Birnaviridae* and *Picornaviridae* families.

6. A composition for use in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms comprising the "Pituitary Adenylate Cyclase Activating Polypeptide" (PACAP).

7. The composition for use according to ~~of~~ claim 6, wherein the PACAP is ~~obtained) by isolation from its~~ natural ~~source~~, ~~b)~~ synthetically or ~~c) by~~ recombinant ~~DNA technology~~.

8. The composition for use according to ~~of~~ claim 6, ~~characterized because it is~~wherein the composition is suitable for use in oral ~~administered~~ administration~~orally~~, ~~by~~ in injection~~,~~ or ~~by~~ immersion baths.

9. The composition for use according to ~~of~~ claims 7 ~~and~~ or 8, ~~characterized because the~~wherein the PACAP is a ~~polypeptide sequence isolated from~~ natural fish PACAP.

10. Veterinary combination comprising the "Pituitary Adenylate Cyclase Activating Polypeptide" (PACAP) and an antiviral molecule, wherein the antiviral molecule is a chemical compound pharmaceutically accepted for the treatment of viral infections.

11. The combination of claim 10 wherein the PACAP is ~~obtained) by isolation from its~~ natural ~~source~~, ~~b)~~ synthetically~~,~~ or ~~c) by~~ recombinant ~~DNA technology~~.

12. The combination of claim 10 wherein the antiviral molecule is VIROTOP, ribavirin, amantadine or ~~a ribavirin analog~~ 5-ethynyl-1-β-D-ribofuranosylimidazole-carboxamide (EICAR).

13. The combination of claim 10, wherein the PACAP and the antiviral molecule are formulated foradministered simultaneously, separately or sequentially administration during the same treatment.

14. The combination of claims 10 to 13 characterized by itsfor use in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms.

15. The combination of for use according to claim 14 wherein the PACAP and the antiviral molecule are administered formulated for orally administration, by administration in injection or administration by immersion baths.

16. The combination of claim 10 where the antiviral molecule is a chemical compound pharmaceutically accepted for the treatment of viral infections, an analog, a functional derivative or active fragment thereof.

1716. The combination of for use according to claim 15, characterized because it iswherein it is formulated for being applied as part of a formulated feed, wherein the PACAP is at a concentration of 50-750 µg/kg of feed and the antiviral compound molecule is at a concentration of 100 to 2000 mg / kg of feed.

1817. The combination of for use according to claim 15 characterized becausewherein it is formulated for being applied by injection, wherein the PACAP is applied at a concentration of 0.1-10 µg per gram of body weight (gbw) and the antiviral molecule at a concentration of 1-50 µg/gbw.

1918. The combination of for use according to claim 15 characterized becausewherein it is formulated for being applied by immersion baths, wherein the PACAP is applied at a concentration of 50-1000 µg per liter of water and the antiviral molecule is applied at a concentration of 100-2000 µg/L of water.

20. Method for the control of viral infections in aquaculture comprising the administration of PACAP or veterinary combinations comprising PACAP to cultured aquatic organisms.